Briya has been selected from among hundreds of applications as one of five contributors to the Biogen HLTH Rare Disease Accelerator – an important new initiative spotlighting companies addressing some of the most complex challenges in rare disease.
Led by Biogen and the HLTH Foundation, the accelerator supports organizations driving innovation in diagnosis, treatment, data access, and patient care. Biogen’s current rare disease portfolio primarily focuses on neuromuscular disorders such as Friedreich’s Ataxia, Spinal Muscular Atrophy, and Amyotrophic Lateral Sclerosis (ALS), with plans to expand into additional therapeutic areas, including liver health, in the near future.
Briya was selected for its advanced data access and analysis capabilities, leveraging AI and NLP to enhance data interpretation, enable complete longitudinal patient journeys, and support highly accurate identification of trends, symptoms, and disease progression.
Advancing Rare Disease Research as Key in Treatment Optimization
Over 300 million people worldwide live with a rare disease, yet the vast majority face delayed diagnoses, limited treatment options, and inadequate disease management. These challenges are largely driven by a lack of accessible data, reliable detection methods, and consequently, insufficient understanding of rare diseases.
The key to optimizing treatment and improving outcomes lies in advancing research. This research depends on reliable, up-to-date, longitudinal, and comprehensive patient-level data.Briya’s global RWD network functions as the gateway to this data – making it easier accessible, while advanced AI and NLP-capabilities support research efficiency and accuracy.
Briya’s selection as a contributor to the Biogen HLTH Rare Disease Accelerator affirms our pivotal role in shaping the future of rare disease research and enabling data-driven healthcare innovation.
Check out Briya’s Dynamic Dataset on Duchenne Muscular Dystrophy.
Related articles
Expanding Access to European Real-World Data: Briya’s New Partnership with Casa Sollievo della Sofferenza
Accessing high-quality European RWD has always been a c...
Read more
Real-World Data: The 21st Century Take on Epidemiology
Is Real-World Data (RWD) just modern epidemiology in di...
Read more
Unlocking the Power of Health Data Through HIPAA Expert Determination
De-Identification as a Foundation for Responsible Innov...
Read more
